Spain Oncology Clinical Trials Market Report 2022 to 2030

Spain Oncology Clinical Trials Market Analysis

$ 3999

Spain's oncology clinical trials market is projected to grow from $244.1 Mn in 2022 to $347.2 Mn by 2030, registering a CAGR of 4.5% during the forecast period of 2022-30. The market will be driven by the rising frequency of cancer in the population and the country's well-developed clinical research infrastructure. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis AG, FHoffmann-La Roche Ltd & Grifols.

ID: IN10ESCT006 CATEGORY: Clinical Trials GEOGRAPHY: Spain AUTHOR: Vidhi Upadhyay

Buy Now

Spain Oncology Clinical Trials Market Executive Summary

Spain's oncology clinical trials market is projected to grow from $244.1 Mn in 2022 to $347.2 Mn by 2030, registering a CAGR of 4.5% during the forecast period of 2022-30. With a population of almost 47 million people, Spain is the fourth-largest nation in the European Union. Yet, Spain is regarded foremost not just because of its size, but also because of its unique expertise in conducting Clinical Trials in a variety of therapeutic sectors. Spain accounted for 4.1% of worldwide Clinical Trials activity in 2021. Moreover, Spain dramatically expanded the participant base in the last year, reaching roughly 145 000 Patients in over 3 400 Clinical Studies. More than 276 thousand new instances of cancer were projected to be identified in Spain in 2021, with 159 thousand in males and 117 thousand in women. With more than 43 thousand new cases in 2021, bowel cancer, commonly known as colon cancer, is the kind with the greatest incidence in the nation, followed by prostate and breast cancer with 35.8 and 33.4 thousand, respectively.

Oncology clinical trials in Spain are an essential aspect of the country's healthcare system since they enable the development of novel cancer treatments and cures. Many research organizations and hospitals in Spain such as Vall d'Hebron Institute of Oncology, Hospital Universitario 12 de Octubre, Hospital Universitario Virgen del Rocio, Hospital Clinic Barcelona & Catalan Institute of Oncology are actively participating in cancer clinical trials, and the nation has a well-developed regulatory framework in place to assure patient safety and ethical trial conduct. Immunotherapy research for several forms of cancer, such as melanoma, lung cancer, and breast cancer, is among the active oncology clinical trials in Spain. There are additional studies focusing on targeted medicines for certain cancers, such as ovarian and pancreatic cancer.

In July 2022, Labcorp (a leading global life sciences company) entered into a collaboration with the MD Anderson Cancer Center Foundation Spain in order to improve access to early-phase oncology clinical trials.

spain oncology clinical trials market analysis

Market Dynamics

Market Growth Drivers

Many reasons are driving the expansion of cancer clinical trials in Spain. One of the key factors is the country's well-developed clinical research infrastructure. Spain has a substantial and well-trained healthcare staff, as well as a robust network of hospitals and research facilities capable of conducting clinical trials. Moreover, the Spanish government has been supportive of clinical research and has adopted rules and regulations to encourage the discovery of novel cancer cures and therapies.

The rising frequency of cancer in the population is another reason driving the expansion of oncology clinical trials in Spain. Cancer rates in Spain, like many other nations, have risen in recent years, increasing the need for novel and more effective therapies. Clinical trials are required for the development of these therapies, and as a result, the number of studies being undertaken in the nation has increased.

Market Restraints

There are also various constraints impeding the expansion of cancer clinical trials in Spain. One of the major constraints is the scarcity of finance for clinical research. Clinical trials may be costly to carry out, and many hospitals and research facilities in Spain have inadequate resources to support this work. Moreover, the nation has a scarcity of trained clinical research specialists, making it challenging to attract and retain employees for clinical studies. Another impediment to the expansion of cancer clinical trials in Spain is the regulatory environment's complexity. Although the Spanish government has enacted laws and regulations to support clinical research, hospitals, and research institutes, especially those that are new to conducting clinical trials, may find it difficult to navigate these rules.

Competitive Landscape

Key Players

Novartis AG
FHoffmann-La Roche Ltd
AstraZeneca
Pfizer Inc
Bristol-Myers Squibb
Grifols (ESP)
PharmaMar (ESP)
Oryzon Genomics (ESP)
Sylentis (ESP)

Notable Insights

In October 2022, Scientists determined that a drug that targets the primary cancer-causing gene, MYC, was able to suppress the gene's activity in phase I clinical study for the first time
In July 2022, Labcorp (a leading global life sciences company) entered into a collaboration with the MD Anderson Cancer Center Foundation Spain in order to improve access to early-phase oncology clinical trials

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation

6. Methodology and Scope

Oncology Clinical Trials Market Segmentation

By Phase (Revenue, USD Billion):

Phase I
Phase II
Phase III
Phase IV

By Study Design Outlook (Revenue, USD Billion):

Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle regeneration
Others

By Indication Outlook (Revenue, USD Billion):

Interventional
Observational
Expanded Access

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.